May 11, 2022 / 03:40PM GMT
Geoffrey Christopher Meacham - BofA Securities, Research Division - Research Analyst
Welcome to the second day of the Bank of America Healthcare Conference. My name is Geoff Meacham. I'm the senior biopharma analyst here. And we're thrilled today to have Merck on stage with us, and we have Caroline Litchfield. Caroline, welcome.
Caroline Litchfield - Merck & Co., Inc. - Executive VP & CFO
Thank you. Excited to be here and thanks for joining this session.
Questions and Answers:
Geoffrey Christopher Meacham - BofA Securities, Research Division - Research AnalystIt's great to do these in person now. I know we've all been pretty tired of Zoom. But let's talk sort of higher level. A lot of the questions on Merck that we've got, and I'm sure a lot of the ones you've gotten are your oncology business is very successful, but it's just grown in concentration. And today's sort of TIGIT news kind of shows that drug development is a risky business. But how are you thinking about that on the back of the Organon spin